Common use of Agreement Preamble Clause in Contracts

Agreement Preamble. Alliance Manager 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Preamble Audited Party 11.6 Base Product 1.69 [***] 1.113 Burdened Technology 3.3.3(a) Burdened Technology Clearance 3.3.3(b) Burdened Technology Limitations 3.3.3(a) Ceasing Party 13.5.3 Co-Commercialization Budget 6.2 Co-Development Budget 5.1 Collaboration Joint Patent Rights 9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 TERM Location Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 Effective Date Preamble Elected Unilateral Adaptimmune Product License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(b) Existing Agreement Preamble First Collaboration Target Nomination Date 3.2.1 Indemnitee 16.3 Indemnitor 16.3 Indirect Taxes 11.9.2 JCC 2.7.1 JDC 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses 16.1 Non-Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out Notice 5.3 Other Component 1.69 Parties Preamble Party Preamble Phase 1 Data Availability Date 4.10.1 Phase 1 Success Criteria 4.1 Publishing Party 12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Notice 17.2.3(a) Royalty Conversion Payments 17.2.3(f) 18 TERM Location Rules 14.2.1 Sale Transaction 17.2.1 Second Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 Term 13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Third Party Claim 16.1 Third Party License 11.4.6(b) Unilateral Adaptimmune Product Elected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Unilateral Adaptimmune Product-Specific Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Unilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Universal Cells Acquisition 17.2.2(a) Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product Elected License Notice 9.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.1

Agreement Preamble. Alliance Manager 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Preamble Audited Party 11.6 Base Product 1.69 Annual Royalty Cap 4.5.1(b) BBA LIBOR 1.47 “[***] 1.113 Burdened Technology 3.3.3(a) Burdened Technology Clearance 3.3.3(b) Burdened Technology Limitations 3.3.3(a) Ceasing Party 13.5.3 Co-Commercialization Budget 6.2 Co-Development Budget 5.1 ]” Preamble “[***]” Indemnitees 10.2 Claim 10.1 Clinical Collaboration Joint Patent Rights 9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Product Supply 3.3.5 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a1.53 Commercial Period 3.1 Commercial Period Milestone Event 4.4.1 Commercial Period Milestone Payment 4.4.1 Commercial Supply Agreement 3.3.6(b) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 TERM Location Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 “[***]” Preamble Effective Date Preamble Elected Unilateral Adaptimmune Product Failure of PART B Deliverables 2.3.2(b) Field Expansion 2.5 FCPA 9.2.15 Gross Sales 1.53 Indemnified Party 10.3 Indemnifying Party 10.3 Infringement 7.2.1 Infringement Notice 7.2.1 Insolvency Event 8.2.4 NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE. Intec Pharma Preamble Intec Pharma Indemnitees 10.1 Intec Pharma-Owned Technology 9.2.12 License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(bFee 4.2 Losses 10.1 Manufacturing Know-How 3.3.7 Option 2.4.2 Option Exercise Date 2.4.2 Option Exercise Notice 2.4.2 Option Exercise Period 2.4.1 PART A Deliverables 2.3.2(a) Existing Agreement Preamble First Collaboration Target Nomination Date 3.2.1 Indemnitee 16.3 Indemnitor 16.3 Indirect Taxes 11.9.2 JCC 2.7.1 JDC 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses 16.1 Non-Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out PART B Deliverables 2.3.2(b) PART B Election Notice 5.3 Other Component 1.69 2.3.2(a) Party/Parties Preamble Party Preamble Patent Coordinator 6.5 Phase 1 Data Availability Date 4.10.1 Clinical Trial Materials 2.3.2(b) Phase 1 Success Criteria 4.1 Publishing Party 12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Materials Acceptance Date 2.3.2(b) Pre-Commercialization Collaboration Notice 17.2.3(a) Royalty Conversion Payments 17.2.3(f) 18 TERM Location Rules 14.2.1 Sale Transaction 17.2.1 Second Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 3.3.2 Pre-Commercialization Plan 3.3.2 Research Period 2.1 Research Period Milestone Event 4.3.1 Research Period Milestone Payment 4.3.1 Sunshine Act 9.2.15 Technology Transfer 3.3.7 Term 13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Third Party Claim 16.1 Third Party License 11.4.6(b) Unilateral Adaptimmune Product Elected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Unilateral Adaptimmune Product-Specific Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Unilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Universal Cells Acquisition 17.2.2(a) Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product Elected License Notice 9.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.1U.S. GAAP 1.53 UK Bribery Act 9.2.15

Agreement Preamble. Alliance Manager 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Preamble 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 11.6 Base 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Definition Section Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.69 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] 1.113 Burdened Technology 3.3.3(aPost-Approval Commitments 6.7(b) Burdened Technology Clearance 3.3.3(bPPQ 7.4(a) Burdened Technology Limitations 3.3.3(aProduct Infringement 14.4(a) Ceasing Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 13.5.3 Co-Commercialization Budget 6.2 Co-Development Budget 5.1 Collaboration Joint Patent Rights 9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 TERM Location Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 Effective Date Preamble Elected Unilateral Adaptimmune Product License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(b) Existing Agreement Preamble First Collaboration Target Nomination Date 3.2.1 Indemnitee 16.3 Indemnitor 16.3 Indirect Taxes 11.9.2 JCC 2.7.1 JDC 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses 16.1 Non-Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out Notice 5.3 Other Component 1.69 Parties Preamble Party Preamble Phase 1 Data Availability Date 4.10.1 Phase 1 Success Criteria 4.1 Publishing Party 12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Notice 17.2.3(aRequest Period 2.8 Review Period 11.1(b) Royalty Conversion Payments 17.2.3(fFloor 9.6(c)(iii) 18 TERM Location Rules 14.2.1 Sale Transaction 17.2.1 Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Definition Section Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 Term IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Third Party Claim 16.1 Third Party License 11.4.6(b) Unilateral Adaptimmune Product Elected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Unilateral Adaptimmune Product-Specific Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Unilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Universal Cells Acquisition 17.2.2(a) Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product Elected License Notice 9.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.11.79 Zymeworks Publication 11.1(c)

Agreement Preamble. Alliance Manager 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Annual Royalty Cap 4.5.1(b) BBA LIBOR 1.47 Biogen Preamble Audited Party 11.6 Base Biogen Indemnitees 10.2 Claim 10.1 Clinical Collaboration Product 1.69 Supply 3.3.5 Combination Product 1.53 Commercial Period 3.1 Commercial Period Milestone Event 4.4.1 Commercial Period Milestone Payment 4.4.1 Commercial Supply Agreement 3.3.6(b) “[***] 1.113 Burdened Technology 3.3.3(a) Burdened Technology Clearance 3.3.3(b) Burdened Technology Limitations 3.3.3(a) Ceasing Party 13.5.3 Co-Commercialization Budget 6.2 Co-Development Budget 5.1 Collaboration Joint Patent Rights 9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 TERM Location Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 ]” Preamble Effective Date Preamble Elected Unilateral Adaptimmune Product Failure of PART B Deliverables 2.3.2(b) Field Expansion 2.5 FCPA 9.2.15 Gross Sales 1.53 Indemnified Party 10.3 Indemnifying Party 10.3 Infringement 7.2.1 Infringement Notice 7.2.1 Insolvency Event 8.2.4 NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE. Intec Pharma Preamble Intec Pharma Indemnitees 10.1 Intec Pharma-Owned Technology 9.2.12 License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(bFee 4.2 Losses 10.1 Manufacturing Know-How 3.3.7 Option 2.4.2 Option Exercise Date 2.4.2 Option Exercise Notice 2.4.2 Option Exercise Period 2.4.1 PART A Deliverables 2.3.2(a) Existing Agreement Preamble First Collaboration Target Nomination Date 3.2.1 Indemnitee 16.3 Indemnitor 16.3 Indirect Taxes 11.9.2 JCC 2.7.1 JDC 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses 16.1 Non-Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out PART B Deliverables 2.3.2(b) PART B Election Notice 5.3 Other Component 1.69 2.3.2(a) Party/Parties Preamble Party Preamble Patent Coordinator 6.5 Phase 1 Data Availability Date 4.10.1 Clinical Trial Materials 2.3.2(b) Phase 1 Success Criteria 4.1 Publishing Party 12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Materials Acceptance Date 2.3.2(b) Pre-Commercialization Collaboration Notice 17.2.3(a) Royalty Conversion Payments 17.2.3(f) 18 TERM Location Rules 14.2.1 Sale Transaction 17.2.1 Second Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 3.3.2 Pre-Commercialization Plan 3.3.2 Research Period 2.1 Research Period Milestone Event 4.3.1 Research Period Milestone Payment 4.3.1 Sunshine Act 9.2.15 Technology Transfer 3.3.7 Term 13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Third Party Claim 16.1 Third Party License 11.4.6(b) Unilateral Adaptimmune Product Elected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Unilateral Adaptimmune Product-Specific Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Unilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Universal Cells Acquisition 17.2.2(a) Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product Elected License Notice 9.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.1U.S. GAAP 1.53 UK Bribery Act 9.2.15

Agreement Preamble. Alliance Manager 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Preamble 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 11.6 Base 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.69 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] 1.113 Burdened Technology 3.3.3(aPost-Approval Commitments 6.7(b) Burdened Technology Clearance 3.3.3(bPPQ 7.4(a) Burdened Technology Limitations 3.3.3(aProduct Infringement 14.4(a) Ceasing Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 13.5.3 Co-Commercialization Budget 6.2 Co-Development Budget 5.1 Collaboration Joint Patent Rights 9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 TERM Location Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 Effective Date Preamble Elected Unilateral Adaptimmune Product License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(b) Existing Agreement Preamble First Collaboration Target Nomination Date 3.2.1 Indemnitee 16.3 Indemnitor 16.3 Indirect Taxes 11.9.2 JCC 2.7.1 JDC 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses 16.1 Non-Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out Notice 5.3 Other Component 1.69 Parties Preamble Party Preamble Phase 1 Data Availability Date 4.10.1 Phase 1 Success Criteria 4.1 Publishing Party 12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Notice 17.2.3(aRequest Period 2.8 Review Period 11.1(b) Royalty Conversion Payments 17.2.3(fFloor 9.6(c)(iii) 18 TERM Location Rules 14.2.1 Sale Transaction 17.2.1 Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 Term IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Third Party Claim 16.1 Third Party License 11.4.6(b) Unilateral Adaptimmune Product Elected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Unilateral Adaptimmune Product-Specific Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Unilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Universal Cells Acquisition 17.2.2(a) Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product Elected License Notice 9.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.11.79 Zymeworks Publication 11.1(c)